Topics

Plexxikon, Inc. Company Profile

12:24 EDT 5th April 2020 | BioPortfolio

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. The company is developing a portfolio of clinical and preclinical stage compounds to address significant unmet medical needs in cardio-renal disease, CNS disorders, autoimmune and neuro-inflammatory diseases, and oncology. Plexxikon’s proprietary Scaffold-Based Drug Discovery™ platform integrates multiple state-of-the-art technologies, including structural screening as a key component that provides a significant competitive advantage over other drug discovery approaches. For more information, please visit www.plexxikon.com.


News Articles [2 Associated News Articles listed on BioPortfolio]

Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

--Co-founder, former CEO of Plexxikon brings proven track record building platform-based companies and delivering novel medicines for patients-- Escient Pharmaceuticals, Inc., a biotechnology compan...

Global Anaplastic Thyroid Cancer Drug Market Data Survey Report 20152025 [Published by HeyReport] Prices from USD $1275

SummaryThe global Anaplastic Thyroid Cancer Drug market will reach xxx Million USD in 2020 with CAGR xx% 20202025. The main contents of the report including:Global market size and forecastRegional mar...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

This open-label single arm study will assess the efficacy, safety and tolerability of RO5185426 in previously treated patients with metastatic melanoma. Patients will receive oral RO518542...

Companies [2 Associated Companies listed on BioPortfolio]

Plexxikon, Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, ...

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, ...

More Information about "Plexxikon, Inc." on BioPortfolio

We have published hundreds of Plexxikon, Inc. news stories on BioPortfolio along with dozens of Plexxikon, Inc. Clinical Trials and PubMed Articles about Plexxikon, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Plexxikon, Inc. Companies in our database. You can also find out about relevant Plexxikon, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record